| Description | This antibody is a human IgG specific for Spike S1 of SARS-CoV-2. It binds to an epitope between RBD-5 and RBD-7 (Class 3) that has slight overlap with the ACE2-binding site. The mAb broadly neutralized all the tested variants, including the most antibody-evasive variants XBB.1.5, XBB, BQ.1.1, and BA.2.75.2. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (Beta, Delta, Omicron BA.1, BA.2, XBB.1.5, XBB and BQ.1.1) |
| Epitope | An epitope between RBD-5 and RBD-7 (Class 3), which has slight overlap with the ACE2-binding site. |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | The neutralizing capacity was tested by Neutralization assay and the results demonstrated that it had moderate IC₅₀ values ranging from 11 to 1149 ng/mL. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
